(Q52526726)

English

Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.

scientific article published in June 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

1 reference

based on heuristic

inferred from title

Nungavarm S. Ramamurthy

4

object named as

N S Ramamurthy

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

author name string

W Pruzanski

1

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

E Stefanski

2

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

P Vadas

3

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

language of work or name

0 references

publication date

1 June 1997

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

Biochemical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

53

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

12

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

1901-1907

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Current management of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Sulphasalazine inhibition of human granulocyte activation by inhibition of second messenger compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Inflammatory effect of intradermal administration of soluble phospholipase A2 in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Purification and characterization of a phospholipase A2 from human ileal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Initiation of anastomotic recurrence of Crohn's disease after ileocolic resection. Onset proximal to the junction and preceded by increased phospholipase A2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Interleukin-1 beta, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Insulin-like growth factors counteract the effect of interleukin 1β on type II phospholipase A2 expression and arachidonic acid release by rabbit articular chondrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Induction of circulating group II phospholipase A2 expression in adults with malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900137-8

7 January 2021

Identifiers

10.1016/S0006-2952(97)00137-8

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

release_gi5qaekd7jeezkp4hysir2ilsu

1 reference

https://api.fatcat.wiki/v0/release/gi5qaekd7jeezkp4hysir2ilsu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 May 2018

http://europepmc.org/abstract/MED/9256165

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52526726&oldid=1844221815"